Scienture Holdings, Inc. (SCNX)
SCNX moved a median of -0.96% 30 minutes after news, and -2.21% by the close. How SCNX actually reacts to news — the realized, point-in-time move the market made, measured across 92 labeled events over the last three years with zero look-ahead.
SCNX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.28% | 38% | 87 |
| 30-min | -0.96% | 32% | 88 |
| 60-min | -1.15% | 37% | 89 |
| to close | -2.21% | 36% | 88 |
| Middle 50% of SCNX reactions | -4.11% to +1.38% |
|---|---|
| Median reaction (30-min) | -0.96% |
| Measured reactions | 92 |
Half of all Scienture Holdings, Inc. news events land between -4.11% and +1.38% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SCNX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SCNX's baseline. Nothing else.
Recent SCNX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Scienture Holdings, Inc. For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | +1.71% | +4.45% | |
| SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth | Press release | GlobeNewswire | -5.09% | -17.56% | |
| Form 8-K Scienture Holdings, Inc. For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | -4.58% | -9.39% | |
| SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals | Press release | GlobeNewswire | -1.33% | -24.60% | |
| Scienture Holdings, Inc. Announces Reverse Stock Split | Press release | GlobeNewswire | -2.72% | -13.86% | |
| Form 8-K Scienture Holdings, Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -0.18% | +2.73% | |
| SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner | Press release | GlobeNewswire | +3.17% | -11.46% | |
| Form DEF 14A Scienture Holdings, Inc. For: Sep 18 | SEC filing · Form DEF | SEC EDGAR | +0.26% | -2.21% | |
| Form 8-K Scienture Holdings, Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -1.12% | -4.74% | |
| SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 | Press release | GlobeNewswire | +3.78% | +7.97% | |
| Form PRE 14A Scienture Holdings, Inc. For: Sep 08 | SEC filing · Form PRE | SEC EDGAR | +3.78% | +7.97% | |
| Form 8-K Scienture Holdings, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -2.08% | -6.31% | |
| SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance | Press release | GlobeNewswire | -3.62% | +2.00% | |
| Form 10-Q Scienture Holdings, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.62% | +2.00% | |
| SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray | Press release | GlobeNewswire | -5.71% | +7.14% | |
| SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers | Press release | GlobeNewswire | -5.99% | -1.80% | |
| SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide | Press release | GlobeNewswire | -2.18% | -7.33% | |
| SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team | Press release | GlobeNewswire | -0.25% | +2.23% | |
| SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC | Press release | ACCESS Newswire | +0.52% | +1.17% | |
| SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041 | Press release | GlobeNewswire | -3.67% | -3.84% | |
| Form 8-K Scienture Holdings, Inc. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | +7.95% | +3.99% | |
| Form 8-K Scienture Holdings, Inc. For: May 18 | SEC filing · Form 8-K | SEC EDGAR | +1.00% | +0.00% | |
| SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion | Press release | GlobeNewswire | -0.71% | -3.72% | |
| Form 10-Q Scienture Holdings, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.71% | -3.72% | |
| Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline | Press release | GlobeNewswire | -2.76% | +4.58% | |
| SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041 | Press release | GlobeNewswire | +4.59% | -0.23% | |
| Form 8-K Scienture Holdings, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +4.59% | -0.23% | |
| Form 8-K Scienture Holdings, Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +3.69% | -2.54% | |
| Form 10-K/A Scienture Holdings, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.79% | +2.87% | |
| Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement | Press release | GlobeNewswire | +0.03% | +14.97% | |
| Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead | Press release | GlobeNewswire | -4.48% | +6.14% | |
| Form 10-K Scienture Holdings, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.10% | -41.52% | |
| SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -4.10% | -41.52% | |
| SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions | Press release | GlobeNewswire | -4.23% | -24.25% | |
| SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium | Press release | GlobeNewswire | +0.40% | -5.72% | |
| SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment | Press release | GlobeNewswire | +0.78% | -10.53% | |
| SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA | Press release | GlobeNewswire | +1.65% | -8.62% | |
| SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium | Press release | GlobeNewswire | -5.98% | -14.20% | |
| SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 | Press release | GlobeNewswire | -0.28% | -1.69% | |
| Form 8-K Scienture Holdings, Inc. For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | +1.39% | +12.09% | |
| Form 8-K Scienture Holdings, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -1.84% | -7.61% | |
| SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.44% | — | |
| Form 10-Q Scienture Holdings, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.44% | — | |
| SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans | Press release | GlobeNewswire | +1.16% | -17.24% | |
| Form 8-K Scienture Holdings, Inc. For: Oct 24 | SEC filing · Form 8-K | SEC EDGAR | +2.63% | +3.47% | |
| Form 8-K Scienture Holdings, Inc. For: Oct 20 | SEC filing · Form 8-K | SEC EDGAR | -9.03% | -22.92% | |
| Form DEF 14A Scienture Holdings, Inc. For: Oct 23 | SEC filing · Form DEF | SEC EDGAR | -4.43% | -18.65% | |
| SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium) | Press release | GlobeNewswire | -5.87% | +185.71% | |
| Form 8-K Scienture Holdings, Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +4.21% | -2.17% | |
| Form 8-K Scienture Holdings, Inc. For: Oct 10 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | -3.50% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SCNX section they belong to.
Where else SCNX is measured.
SCNX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Scienture Holdings, Inc.'s median reaction calculated?
Every labeled SCNX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 92 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 32% of SCNX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SCNX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.